SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company will be presenting at two investor conferences the week of June 12, 2006, during which it is scheduled to present a corporate overview of the company and its clinical development and discovery programs. The conference information is as follows:
Live webcasts of the presentations will be available under the investor relations section of Arena's website at http://www.arenapharm.com. Replays of the presentations will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focusing its research and development efforts on small molecule drugs in four major therapeutic areas: metabolic, central nervous system, cardiovascular and inflammatory diseases. Arena is developing a broad pipeline of compounds targeting an important class of drug targets called G protein-coupled receptors, or GPCRs, using its knowledge of GPCRs and its technologies, including CART™ and Melanophore. Arena has four internally discovered, clinical-stage drug candidates for major diseases. The most advanced, lorcaserin hydrochloride, is under investigation for the treatment of obesity. Arena's lead drug candidate for the treatment of insomnia, APD125, is a compound with a novel mechanism of action. Arena also has two clinical-stage collaborations with major pharmaceutical companies: Merck & Co., Inc. and Ortho-McNeil, Inc.
SOURCE Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President and CEO, or David Walsey, Director,
Corporate Communications, both of Arena Pharmaceuticals, Inc.,
+1-858-453-7200, ext. 1682; or Carolyn Wang, Media Relations, WeissComm
Partners, +1-415-946-1065, for Arena Pharmaceuticals, Inc.
Web site: http://www.arenapharm.com
